POM-V Prescription Required

Finadyne 50 mg/g Oral Paste

Active ingredient: Flunixin

Form

Paste

Species

Horses

Manufacturer

Intervet International B.V.

VMD MA No.

06376/4089

What it's used for

AN: 00849/2023Page 2 of 8

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Flunixin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Finadyne 50 mg/g Oral Paste — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

AN: 00849/2023Page 2 of 8

response.
Each 10 g syringe is sufficient for one day’s treatment for a 454 kg (1000 lb.) horse.
The syringe is calibrated in 100 kg increments to facilitate dosing of horses of
different weights.
Prior to first use, the syringe must be primed. Set the ring on the graduated syringe
plunger to the zero (0) position. Remove the cap and press the plunger to remove air.
Discard any small volume of paste that may be expelled. The syringe is now ready for
use.

Do not exceed the stated dose or duration of treatment.
Do not use in animals suffering from cardiac, hepatic or renal disease, or where there
is the possibility of gastrointestinal ulceration or bleeding.
Do not use in cases of hypersensitivity to the active substance.
Do not administer steroidal or other non-steroidal anti-inflammatory drugs
concurrently or within 24 hours of each other.
Do not use in hypovolaemic animals except in the case of endotoxaemia or septic
shock.

Horses:
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Allergic reaction (e.g., allergic skin
reaction, anaphylaxis)
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Non-steroidal anti-inflammatory drugs are not permitted substances under the rules of
racing and under rules covering other competitive events. The Royal College of
Veterinary Surgeons has given guidance to the Veterinary profession regarding the
use of anti-inflammatory drugs in competing horses. It states that if a veterinarian
recommends the discontinuation of any such drug not less than eight days before
racing he should feel sure he has catered for all but the most exceptional case.

Special precautions for safe use in the target species:
Use in animals less than 6 weeks of age or in aged animals may involve additional
risk.
If such use cannot be avoided animals may require a reduced dosage and careful
clinical management.
In animals undergoing general anaesthesia it is preferable to wait until they are fully
recovered before the veterinary medicinal product is administered.
NSAIDs can cause inhibition of phagocytosis. During use in the treatment of
inflammatory conditions associated with bacterial infections, appropriate concurrent
antimicrobial therapy should be administered.
Avoid use in dehydrated, hypovolaemic or hypersensitive animals as there is a
potential risk of increased renal toxicity.
Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to
enter wild fauna food chain. In case of death or sacrifice of treated animals, ensure
that they are not made available to wild fauna.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Avoid contact with eyes and direct contact with skin. In the case of accidental contact
with eyes, rinse immediately with plenty of water and seek medical advice and show
the package leaflet or the label to the physician.
The veterinary medicinal product may cause reactions in sensitive individuals.
Reactions may be serious.
People with known hypersensitivity to non-steroidal anti-inflammatory products,
should avoid handling the veterinary medicinal product.
Personal protective equipment consisting of gloves should be worn when handling the
veterinary medicinal product during application.
Wash hands and exposed skin after use.
Special precautions for the protection of the environment:
Not applicable.

Concurrent administration of potentially nephrotoxic drugs should be avoided.
Some NSAIDs may be highly bound to plasma proteins and may compete with other
highly bound drugs to produce an increase in non-bound pharmacologically active
concentrations which can lead to toxic effects.

Do not store above 25 °C.
Do not freeze.
Replace cap after use.
Keep syringes in the outer box.
Store syringes in an upright position.

Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under
national horse passport legislation.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.